Cart
sales@molnova.com
RBN012759
CAS No. 2360851-29-0
RBN012759( —— )
Catalog No. M22469 CAS No. 2360851-29-0
RBN012759, a potent and selective PARP14 inhibitor, decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 274 | In Stock |
|
| 2MG | 149 | In Stock |
|
| 5MG | 250 | In Stock |
|
| 10MG | 372 | In Stock |
|
| 25MG | 645 | In Stock |
|
| 50MG | 918 | In Stock |
|
| 100MG | 1283 | In Stock |
|
| 200MG | 1730 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRBN012759
-
NoteResearch use only, not for human use.
-
Brief DescriptionRBN012759, a potent and selective PARP14 inhibitor, decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants.
-
DescriptionRBN012759, a potent and selective PARP14 inhibitor, decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetPARP
-
RecptorPARP14
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2360851-29-0
-
Formula Weight378.46
-
Molecular FormulaC19H23FN2O3S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (660.57 mM)
-
SMILESO[C@H]1CC[C@@H](CC1)SCc1nc2cc(OCC3CC3)cc(F)c2c(=O)[nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Schenkel L, et, al. A potent and selective PARP14 inhibitor decreases pro-tumor macrophage function and elicits inflammatory responses in tumor explants. AACR Annual Meeting 2020.
molnova catalog
related products
-
PARP1-IN-8?
PARP1-IN-8 is an effective inhibito of PARP1 (IC50 = 97 nM).
-
BYK204165
BYK204165 is a potent PARP inhibitor?(PARP1; IC50 = 44.67 nM for human recombinant PARP1 in an enzyme assay).
-
MK-4827 Racemate
MK-4827 Racemate is a selective PARP1 and PARP2 inhibitor with IC50s of 3.8 nM and 2.1 nM, respectively, over 330-fold selectivity for PARP3, V-PARP and Tank1.
